This doctoral thesis is based on the following papers
- Makar A P, Kristensen G B, Karn J, Børmer O P, Abeler V M, Tropé CG. Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis. Obstet Gynecol 1992; 79: 1002–10
- Makar A P, Kristensen G B, Børmer O P, Tropé CG. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. Gynecol Oncol 1992; 45: 323–8
- Makar A P, Kristensen G B, Børmer OF', Tropé CG. Serum CA 125 level allows early identification of non-responders during induction chemotherapy. Gynecol Oncol 1993; 49: 73–9
- Makar A P, Kristensen G B, Børmer O P, Tropé CG. Is serum CA 125 level at time of relapse a prognostic indicator for further survival prognosis. Gynecol Oncol 1993; 49: 3–7
- Makar A P, Karn J, Kristensen G B, Børmer O P, Tropé CG. Evaluation of serum CA 125 level as a tumor marker in patients with borderline ovarian tumors. Int J Gynecol Cancer 1993; 3: 299–303
- Makar A P, Holm R, Kristensen G B, Nesland J M, Tropé CG. The expression of c-erbB-2 oncogene in patients with invasive ovarian malignancies. Int J Gynecol Cancer 1994; 4: 1949
- Makar A P, Kristensen G B, Nesland J M, Børmer O P, Tropé CG. Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies. Int Gynecol Cancer 1993; 3: 116–21